(RTTNews) - Specialty pharmaceutical company Talphera, Inc. (TLPH), Monday announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously ...

Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD).

Rege Nephro has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals (SYRS), through a mutual agreement. The acquisition was ...